Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Aeolus Pharmaceuticals (AOLS) Posts Q4, FY 2011 Financial Results, Operational Highlights

|Includes: Aeolus Pharmaceuticals, Inc. (AOLS)

Aeolus Pharmaceuticals Inc. announced its financial results for the three and twelve months ended September 30, 2011, as well as several key operational accomplishments achieved during the year.

Aeolus reported total revenues for full-year 2011 at $4.8 million compared to no revenue in full-year 2010.

Net income for 2011 was $0.3 million, or $0.01 per basic share, which includes a non-cash gain of approximately $3.9 million related to decreases in the fair value of the warrants, as compared to a 2010 loss of $25.9 million, or $(0.53) per basic share, which includes a charge of approximately $21.3 million related to increases in the fair value of the warrants.

For the fourth quarter of 2011, Aeolus reported total revenues at $2.1 million compared to no revenue in 2010.

Net loss for the 2011 fourth quarter was $2.1 million, which includes a gain of approximately $1.1 million related to decreases in the fair value of the warrants, as compared to $12.9 million, which includes a charge of approximately $11.4 million related to increases in the fair value of the warrants, in the fourth quarter of FY 2010.

As of September 30, 2011, the company had cash and cash equivalents of $518,000.

The company also highlighted operational milestones achieved during full-year 2011, including but not limited to:

• Awarded a $118.4 million contract to develop treatment for pulmonary acute radiation syndrome
• Reported positive results from study of AEOL 10150 and Neupogen(NYSE:R)as combination therapy for treatment of acute radiation syndrome
• Research partners awarded more than $13.4 million in research
• grants
• Filed for Orphan Drug designation of AEOL 10150 for mitigation and/or treatment of delayed effects of acute radiation exposure of the lung
• Shored-up balance sheet with additional cash
• Accomplished 11 key milestones under the BARDA Lung ARS development contract

“During fiscal year 2011, we were able to take major steps forward in the development of AEOL 10150, at minimal cost to our shareholders, based on the support of our medical countermeasure development program by BARDA, NIH-NIAID and NIH CounterACT,” John L. McManus, president and CEO stated in the press release. “We look forward to 2012, when we expect to receive a decision on several BARDA options, begin an important human safety study under the BARDA contract that will also support of our oncology program and report key data from several ongoing studies.”

For more information visit aeoluspharma.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net